Sarcomatrix Therapeutics Corp. Opens Seed+ Investment Round to Accredited Investors on the KoreInside Platform
Preclinical-stage Nevada biotech funds its oral, mutation-agnostic Duchenne muscular dystrophy program toward a 2027 IND filing and first-in-human dosing. RENO, NV, UNITED STATES, July 15, 2026 /EINPresswire.com/ -- Sarcomatrix Therapeutics Corp …